Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 19, 2025

OCI-Ly1

RRID:CVCL_1879
Type: Cell Line

Proper Citation

(RRID:CVCL_1879)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1879

Proper Citation: (RRID:CVCL_1879)

Sex: Male

Defining Citation: PMID:3567358, PMID:8574164, PMID:10676951, PMID:11807979, PMID:12169673, PMID:19278952, PMID:19358282, PMID:20628145, PMID:23257783, PMID:23292937, PMID:23699601, PMID:25960936

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: miRNA expression profiling., Omics: H3K9ac ChIP-seq epigenome analysis., Omics: Genome sequenced., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Array-based CGH., From: Ontario Cancer Institute (OCI); Toronto; Canada.

Category: Cancer cell line

Name: OCI-Ly1

Synonyms: OCI-LY1, OCI-ly1, OCI-LY-1, OCI-Ly-1, Oci-Ly-1, OCI-Ly 1, OCI-Ly01, OCI Ly1, Ly1, LY1

Cross References: EFO:EFO_0005907, BioGRID_ORCS_Cell_line:1211, cancercelllines:CVCL_1879, ChEMBL-Cells:CHEMBL4295427, ChEMBL-Targets:CHEMBL4296480, Cosmic:1134602, Cosmic:1295512, Cosmic:1329091, Cosmic:1517641, Cosmic:1541900, Cosmic:1629932, Cosmic:1636682, Cosmic:1945183, Cosmic:2276318, DSMZ:ACC-722, DSMZCellDive:ACC-722, ENCODE:ENCBS397COL, ENCODE:ENCBS729LWO, ENCODE:ENCBS899DSB, ENCODE:ENCBS945KYE, GEO:GSM1957, GEO:GSM380130, GEO:GSM552450, GEO:GSM1035341,

GEO:GSM1059803, GEO:GSM1374783, GEO:GSM3150250, Lonza:1352, PRIDE:PXD012087, Progenetix:CVCL_1879, PubChem_Cell_line:CVCL_1879, Wikidata:Q54931759

ID: CVCL_1879

Record Creation Time: 20250131T202146+0000

Record Last Update: 20250131T203959+0000

Ratings and Alerts

No rating or validation information has been found for OCI-Ly1.

No alerts have been found for OCI-Ly1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. Cell reports. Medicine, 5(2), 101421.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia, 38(10), 2210.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

McNutt SW, et al. (2024) Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation. Research square.

Zhuang X, et al. (2024) Functional genomics identifies N-acetyllactosamine extension of complex N-glycans as a mechanism to evade lysis by natural killer cells. Cell reports, 43(4), 114105.

Groß E, et al. (2023) SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters. Cancers, 15(11).

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research

communications, 3(4), 576.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Schleser SW, et al. (2023) Palladium and Platinum Complexes of the Antimetabolite Fludarabine with Vastly Enhanced Selectivity for Tumour over Non-Malignant Cells. Molecules (Basel, Switzerland), 28(13).

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer discovery, 13(1), 216.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. Cancer discovery, 13(8), 1862.

Kim DY, et al. (2022) Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma. Cancer research and treatment, 54(4), 1256.

Kim DY, et al. (2022) Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. Cancer research and treatment, 54(1), 301.

Wei P, et al. (2022) Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. Science advances, 8(39), eabq0117.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity, 54(1), 116.

Venturutti L, et al. (2020) TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell, 182(2), 297.

Qiu Z, et al. (2020) MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell chemical biology, 27(5), 538.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. Cell reports, 31(13), 107840.

Guièze R, et al. (2019) Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer cell, 36(4), 369.

Lin KH, et al. (2019) Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. Cell metabolism, 29(5), 1217.